drugset / Trial / NCT00142337

One Month Dual Antiretroviral Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose Nevirapine

NCT00142337

Phase 2 Completed 244 enrolled Research Institute for Development
Non-randomizedSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to determine whether providing zidovudine (ZDV) and didanosine (ddI) during labor and for one month postpartum can reduce the selection of nevirapine (NVP) resistance mutations postpartum in women who received a single dose of nevirapine during labor and standard ZDV prophylaxis for the prevention of mother to child transmission of HIV.

Timeline

Start
2004-12
Primary completion
2006-05
Completion
2009-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Didanosine Small molecule 250 mg
Subject Didanosine Small molecule 400 mg
Subject Zidovudine Small molecule 200 mg
Subject Zidovudine Small molecule 300 mg